| Literature DB >> 14518572 |
Abstract
Most patients who should be on lipid-lowering therapy are not receiving it, and most patients who are receiving it are not reaching their appropriate low-density lipoprotein (LDL) goals. This is in part because physicians and patients fear side effects of statins and other lipid-lowering agents. Ezetimibe (Zetia), a new lipid-lowering drug, may help physicians close this "treatment gap" in more patients, especially in combination with a statin.Entities:
Mesh:
Substances:
Year: 2003 PMID: 14518572 DOI: 10.3949/ccjm.70.9.777
Source DB: PubMed Journal: Cleve Clin J Med ISSN: 0891-1150 Impact factor: 2.321